Comorbidities and polypharmacy among HIV-positive patients aged 50 years and over: a case-control study.

ABSTRACT

OBJECTIVE: This study was to determine and compare the prevalences of polypharmacy and comorbidities in patients aged 50 years or older with those patients younger than 50 years in a Mexican population. RESULTS: One hundred and twenty-five patients were enrolled, 60 (48%) were aged 50 years or older. The median CD4+ cell counts were 509 cells/µL (interquartile range [IQR] 324-730) for the older patients and 384 cells/µL (IQR 262-562) (P = 0.021) for the younger patients. Viral suppression were significantly higher in the older group 80% vs. 63% (P = 0.037). The number of comorbidities was significantly higher in the older group, with a median of 2 (IQR 2-3) vs. 1 (IQR 0-1) (P ≤ 0.001). After adjustment of the logistic regression model in the older group, the following comorbidities differed between the age groups systemic arterial hypertension (odds ratio [OR] 15.75; 95% confidence interval [CI] 3.49-71.05; P = < 0.001), diabetes mellitus (OR 14.36; 95% CI 1.79-115.07; P = 0.001), osteoarthritis (OR 10.33; 95% CI 2.88-37.05; P = < 0.001), hyperlipidemia (OR 2.78; 95% CI 1.22-6.34; P = 0.001), and polypharmacy (OR 6.58; 95% CI 3.01-14.39; P = 0.001).